INTS, BIO

J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research

Veröffentlicht: 19.03.2026 um 22:45 Uhr, prnewswire.co.uk

J INTS BIO New York South Korea United States of America United Kingdom

View original content:https://www.prnewswire.co.uk/news-releases/j-ints-bio-reports-fourth-generation-egfr-inhibitor-jin-a02-in-clinical-cancer-research-302686113.html

en | boerse | 68905343 |